Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Long-Term Ibrutinib Follow-up Demonstrates Continued Efficacy in MCL

January 3rd 2018

More than one-quarter of patients with relapsed/refractory mantle cell lymphoma remained progression free and nearly half were alive at 3 years when treated with the BTK inhibitor ibrutinib (Imbruvica).

Highlights from ASH 2017: Mantle Cell Lymphoma

December 23rd 2017

Investigational Treatment in Mantle Cell Lymphoma

December 23rd 2017

Future Therapy: Bruton's TKI Containing Combinations in MCL

December 23rd 2017

Allogeneic Transplantation in Mantle Cell Lymphoma

December 23rd 2017

Acalabrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Ibrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Understanding Relapse in Mantle Cell Lymphoma

December 23rd 2017

Maintenance Therapy in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Autologous Stem Cell Transplantation

December 23rd 2017

Induction Therapy for Mantle Cell Lymphoma

December 23rd 2017

The Watch-and-Wait Approach in Mantle Cell Lymphoma

December 23rd 2017

The Value of MIPI and Ki-67 in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Diagnosing Mantle Cell Lymphoma

December 23rd 2017

Classifying Mantle Cell Lymphoma

December 23rd 2017

Dr. Wang Discusses Acalabrutinib in MCL

December 22nd 2017

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.

NICE Recommends Ibrutinib for Relapsed/Refractory MCL

December 16th 2017

The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.

Expert Emphasizes Importance of Acalabrutinib Approval in MCL

December 14th 2017

Michael Wang, MD, discusses the impact of acalabrutinib on patients with mantle cell lymphoma, ongoing progress in the field, and The University of Texas MD Anderson Cancer Center

Goy Reflects on MCL Data Presented at ASH 2017

December 13th 2017

Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).

Dr. Wang on Acalabrutinib Activity in Mantle Cell Lymphoma

December 12th 2017

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses results from the phase II ACE-LY-004 trial, which explored the BTK inhibitor acalabrutinib (Calquence) in patients with refractory mantle cell lymphoma (MCL).